Merck announces outcome of IIIb study for Kuvan
Merck announced that the Phase IIIb SPARK study has met its primary endpoint. The results of the first 26 weeks of this study demonstrated that the addition of Kuvan® (sapropterin dihydrochloride) to a phenylalanine restricted diet in children less than 4 years of age who have phenylketonuria (PKU) and have been previously shown to be responsive to Kuvan significantly increased tolerance to phenylalanine compared with a phenylalanine-restricted diet alone. The safety profile of Kuvan in this population was consistent with the safety profile for Kuvan described in the European Summary of Product Characteristics. SPARK was requested by the European Medicines Agency (EMA) as a post-authorization measure.
Other news from the department business & finance

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Noble way to low-cost fuel cells, halogenated graphene may replace expensive platinum
Nano-velcro clasps heavy metal molecules in its grips - Researchers develop nano-strips for inexpensive testing of mercury levels in our lakes and oceans with unprecedented sensitivity

Controlling phase changes in solids - A recent study demonstrates the rapid control of phase-changes in resonantly bonded materials
Category:American_pharmacologists
